RxSight, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $RXST in the last 7 days.
No SEC Form 4 filings for $RXST in the last 30 days.
See all $RXST insider activity →RxSight's (RXST) COO exchanged higher-priced stock options for new options at $6.375 per share. The new options have various vesting schedules under the 2021 Equity Incentive Plan, with some vesting monthly over 48 months and others in 2027.
RxSight (RXST) outlined a turnaround plan at the Wells Fargo Healthcare Conference, focusing on increasing use of its Light Adjustable Lens (LAL) among existing surgeons. The company acknowledged commercial execution issues, with stock down 38% YTD. It plans to double its U.S. sales force and highlighted a $200M upfront partnership with Alcon. Management expects a return to growth but did not provide 2027 guidance. Revenue was $127.6M, down 13% YoY, with $210M in cash.
RxSight (RXST) officer Ilya Goldshleger plans to sell 5,370 shares of company stock to cover withholding taxes on vested restricted stock units, according to a Rule 144 notice filed on September 2, 2026, with the sale scheduled for August 31, 2026.
Recent RXST coverage spans financial news, technology and earnings.
The exchange reduces the COO's option strike price, potentially aligning incentives but unlikely to move the stock materially.
The cash infusion and partnership could improve margins and support a turnaround, potentially lifting the stock.
A small insider sale of 5,370 shares is disclosed, indicating modest additional supply but limited price impact.
Minor insider sell of ~$14K; unlikely to move the stock.
The new stake may signal confidence and could influence future board decisions or potential activist interest.
AlphAI scores every news story that mentions RXST with an AI model for sentiment and relevance, and aggregates insider trades from RxSight, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RxSight's (RXST) COO exchanged higher-priced stock options for new options at $6.375 per share. The new options have various vesting schedules under the 2021 Equity Incentive Plan, with some vesting monthly over 48 months and others in 2027.
1 min readRxSight (RXST) outlined a turnaround plan at the Wells Fargo Healthcare Conference, focusing on increasing use of its Light Adjustable Lens (LAL) among existing surgeons. The company acknowledged commercial execution issues, with stock down 38% YTD. It plans to double its U.S. sales force and highlighted a $200M upfront partnership with Alcon. Management expects a return to growth but did not provide 2027 guidance. Revenue was $127.6M, down 13% YoY, with $210M in cash.
3 min readRxSight (RXST) officer Ilya Goldshleger plans to sell 5,370 shares of company stock to cover withholding taxes on vested restricted stock units, according to a Rule 144 notice filed on September 2, 2026, with the sale scheduled for August 31, 2026.
1 min readRxSight (RXST) reported that Chief Business Development Officer Eric Weinberg converted 5,370 RSUs into shares and sold 2,041 shares at $6.96 to cover taxes. Weinberg retains indirect holdings and significant RSUs set to vest by 2029. No discretionary sale or 10b5-1 plan was involved.
1 min readPoint72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported a 6.0% stake in RxSight, Inc. (RXST), owning 2,487,468 shares as of August 18, 2026. The shares are held by Point72 Associates, LLC, with shared voting and dispositive power.
1 min readAlcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.
3 min readSimply Wall St discusses Alcon’s Q2 2026 earnings, saying sales and revenue rose but net income fell, while 2026 net sales growth guidance was maintained. It also cites a RxSight collaboration and notes Alcon’s shares returned 17.97% over 90 days but -13.93% over one year. A “fair value” of CHF76.62 vs CHF59.48 is referenced.
6 min readRxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.
6 min readAlcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST) announced a non-exclusive collaboration to co-develop post-operative adjustable pseudophakic intraocular lenses using RxSight’s light-adjustable technology. Alcon also opened a second training center in India with Aravind. Q1 2026: Alcon net sales $2.7B (+10% YoY), core EPS $0.85, FCF $279M. RxSight revenue $30.9M (-18.5% YoY), net loss $15.9M, gross margin 76.1%.
6 min readRxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financia
6 min read
